UroGen Pharma Ltd
URGN
27.65
-4.08
-12.86%
UroGen Pharma Ltd
US · URGN
#2773 by market cap
Listed 2017
27.65
-4.08
-12.86%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $43Market Newswire · 2026/5/11
-
Rating change
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/5/19
-
Rating change
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75Market Newswire · 2026/8/6
-
Rating change
Urogen Pharma (URGN) Receives a Buy From H.C. WainwrightTipRanks · 2026/5/27
-
Rating change
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44Market Newswire · 2026/7/16
-
Rating change
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/5/7
-
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/10/28
-
Rating change
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42Market Newswire · 2026/7/22
-
Rating change
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/4/20
-
Rating change
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/4/23
-
Rating change
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/8/6
-
Rating change
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/7/22
-
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $56Market Newswire · 2026/11/5
-
Rating change
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/6/16
-
Rating change
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50Market Newswire · 2026/7/16
-
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $58 to $75Market Newswire · 2026/11/6
-
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/11/5
-
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/10/20
-
Rating change
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45Market Newswire · 2026/5/11
-
Rating change
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/7/16
-
Rating change
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/2/13
-
Rating change
Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40Market Newswire · 2026/4/10
-
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/10/20
-
Rating change
Ladenburg Thalmann Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2025/11/8
-
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/8/21
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
UroGen Pharma Ltd discussion 0 comments